163596-75-6

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-NITRO-BENZALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Dye and Pigment Industry:
4-BROMO-3-NITRO-BENZALDEHYDE is utilized as an intermediate in the production of dyes and pigments, playing a crucial role in the creation of colorants for different applications.
Used in Agrochemical Industry:
4-BROMO-3-NITRO-BENZALDEHYDE serves as an intermediate in the synthesis of agrochemicals, aiding in the development of products for agricultural applications such as pesticides and herbicides.
Used in Fragrance Industry:
4-BROMO-3-NITRO-BENZALDEHYDE is used as a component in the synthesis of fragrances, contributing to the creation of various scent profiles for the perfumery and cosmetics sectors.
Used in Antimicrobial Applications:
Leveraging its potent antimicrobial and antifungal properties, 4-BROMO-3-NITRO-BENZALDEHYDE is employed in the development of antimicrobial agents, helping to combat microbial infections and contamination.

InChI:InChI=1/C7H4BrNO3/c8-6-2-1-5(4-10)3-7(6)9(11)12/h1-4H

Upstream product

• 7664-93-9 sulfuric acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 17333-91-4 diazotiertes 4-Amino-benzaldehyd 

Downstream Products

• 1022082-09-2 (2E)-3-(4-bromo-3-nitrophenyl)acrylic acid 
• 1187775-03-6 4-(benzo[b]thiophene-2-yl)-3-nitrobenzaldehyde 
• 1187775-07-0 4-naphthalene-3-nitrobenzaldehyde 
• 1211998-82-1 4-bromo-3-nitrobenzoic acid 3-phenylallyl ester 
• 1335114-87-8 C₁₆H₂₀N₂O₇ 
• 359867-42-8 3-amino-4-bromobenzaldehyde 
• 42860-06-0 4-bromo-3-iodobenzoic acid 
• 619-03-4 3,4-dibromobenzoic acid 
• 53104-41-9 3,5-dinitro-4-methoxybenzaldehyde 
• 25118-59-6 4-bromo-3-chlorobenzoic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of antinociceptive and anti-inflammatory effects of nitro-porphyrins

This manuscript reports the anti-inflammatory and antinociceptive effects of 4 nitrophenyl-porphyrins: 5,10,15,20-tetra-(3-nitrophenyl)-porphyrin (TNPP), 5,10,15,20-tetra-(4-fluoro-3-nitrophenyl)-porphyrin (TpFNPP), 5,10,15,20-tetra-(4-chloro-3-nitrophenyl)-porphyrin (TpClNPP), and 5,10,15,20-tetra-(4-bromo-3-nitrophenyl)-porphyrin (TpBrNPP). The in vivo anti-inflammatory assays were tested on the acute and chronic TPA (12-O-tetradecanoylphorbol 13-acetate) induced ear edema. The in vitro anti-inflammatory assay was carried out using J774A.1 murine macrophages stimulated with LPS. All nitro-porphyrins decreased inflammation significantly in the acute model: 58.55% (TNPP), 67.49% (TpBrNPP), 67.49% (TpClNPP), and 71.32% (TpFNPP). TpFNPP (50 μM/ml) increased the production of the anti-inflammatory cytokine IL-10, and decreased the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 in macrophages activated with LPS, with similar activity than indomethacin (50 μM/ml). All porphyrins showed antinociceptive activity and lacked visible toxicity in the acute toxicity test. These results open the possibility of further studies to determine mechanisms of action, and study the influence of the structure on the activity of such compounds.

BETA-LACTAM COMPOUNDS AND METHODS OF USE THEREOF

Beta-lactam compounds to detect carbapenemases or microbial carbapenem resistance are disclosed. The compounds contain a chemical probe. Upon hydrolysis by carbapenemases, the compounds undergo intramolecular rearrangement and release the chemical probe. Detection of the released chemical probe indicates the presence of carbapenemases and the presence of microbial carbapenem resistance.

A preparation method of the methyl two sulphur are prosperous

The invention relates to a preparation method of the methyl two sulphur are prosperous, to the bromobenzene formaldehyde as the starting material, the nitration reaction occurs first, then and cuprous cyanide reaction, the bromine takes on behalf of the c

Regulating Transition-Metal Catalysis through Interference by Short RNAs

Herein we report the discovery of a AuI–DNA hybrid catalyst that is compatible with biological media and whose reactivity can be regulated by small complementary nucleic acid sequences. The development of this catalytic system was enabled by the discovery of a novel AuI-mediated base pair. We found that AuI binds DNA containing C-T mismatches. In the AuI–DNA catalyst's latent state, the AuI ion is sequestered by the mismatch such that it is coordinatively saturated, rendering it catalytically inactive. Upon addition of an RNA or DNA strand that is complementary to the latent catalyst's oligonucleotide backbone, catalytic activity is induced, leading to a sevenfold increase in the formation of a fluorescent product, forged through a AuI-catalyzed hydroamination reaction. Further development of this catalytic system will expand not only the chemical space available to synthetic biological systems but also allow for temporal and spatial control of transition-metal catalysis through gene transcription.

Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility

The current optimization of IG-105 (3) on the carbazole-ring provided a series of new carbazole sulfonamides derivatives 13a–13m. All of the compounds have been evaluated against HepG2 cells (hepatoma cancer) for antiproliferative activity. Compounds that showed activity better or comparable to that of 3 versus HepG2 were evaluated against MCF-7 (breast cancer), MIA PaCa-2 (pancreatic cancer), and Bel-7402 (hepatoma/liver cancer) for antiproliferative activity. Of the seven compounds selected for further study five (13b, 13g, 13j, 13k and 13l) were found to give IC50values against the four cell lines comparable to those for 3. Two compounds (13f and 13i) were more active than 3 and their activity against HepG2 and MCF-7 (IC50:0.01–0.07?μM) approached that of the positive controls podophyllotoxin (podo) and CA-4. Most of compounds showed aqueous solubility (0.11–19.60?μg/mL at pH 7.4 and 2.0) better than 3. These promising results warrant further development of new compounds 13f and 13i as potential potent antitumor drug candidates.

Thiosemicarbazones as Aedes aegypti larvicidal

Abstract A set of aryl- and phenoxymethyl-(thio)semicarbazones were synthetized, characterized and biologically evaluated against the larvae of Aedes aegypti (A. egypti), the vector responsible for diseases like Dengue and Yellow Fever. (Q)SAR studies were useful for predicting the activities of the compounds not included to create the QSAR model as well as to predict the features of a new compound with improved activity. Docking studies corroborated experimental evidence of AeSCP-2 as a potential target able to explain the larvicidal properties of its compounds. The trend observed between the in silico Docking scores and the in vitro pLC50 (equals -log LC50, at molar concentration) data indicated that the highest larvicidal compounds, or the compounds with the highest values for pLC50, are usually those with the higher docking scores (i.e., greater in silico affinity for the AeSCP-2 target). Determination of cytotoxicity for these compounds in mammal cells demonstrated that the top larvicide compounds are non-toxic.

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

Pyrano, piperidino, and thiopyrano compounds and methods of use

The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.

Potassium channel openers

Compounds having the formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.